Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Ettinger

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Cancer Chemotherapy and Pharmacology|April 2, 2008
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumorsWells A Messersmith, Antonio Jimeno, David Ettinger, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic ChemotherapyCiara C O'Sullivan, Holly K Van Houten, Lindsey R Sangaralingham, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 9, 2019
Lung cancer and family-centered concernsJosephine Feliciano, Alexander Chang, Deepti Venkatraman, et al.
Chest|February 19, 2019
Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral ChemotherapyLonny Yarmus, Christopher Mallow, Jason Akulian, et al.
Clinical Lung Cancer|August 31, 2022
Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung CancerMatthew Z Guo, Joseph C Murray, Paola Ghanem, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 11, 2010
Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa regionAbdul-Rahman Jazieh, Hanaa Bamefleh, Ahmet Demirkazik, et al.
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Cancer Chemotherapy and Pharmacology|April 2, 2008
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumorsWells A Messersmith, Antonio Jimeno, David Ettinger, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic ChemotherapyCiara C O'Sullivan, Holly K Van Houten, Lindsey R Sangaralingham, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 9, 2019
Lung cancer and family-centered concernsJosephine Feliciano, Alexander Chang, Deepti Venkatraman, et al.
Chest|February 19, 2019
Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral ChemotherapyLonny Yarmus, Christopher Mallow, Jason Akulian, et al.
Clinical Lung Cancer|August 31, 2022
Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung CancerMatthew Z Guo, Joseph C Murray, Paola Ghanem, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 11, 2010
Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa regionAbdul-Rahman Jazieh, Hanaa Bamefleh, Ahmet Demirkazik, et al.
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
Pageof 2